Ex-Drug Executive Shkreli to Face U.S. Fraud Trial in June 2017

From Reuters

Martin Shkreli, the former pharmaceutical executive who last year became a lightning rod for criticism of soaring prescription drug prices, is now scheduled to go on trial in June 2017 in the U.S. government's securities fraud case against him.

U.S. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli, 33, and Evan Greebel, a former lawyer for Retrophin Inc (RTRX.O), a biopharmaceutical company which Shkreli founded and headed until 2014.

Read the full article.